Receive a simplified blood-clotting procedure during your dialysis sessions

Recruiting

What is this trial?

Dialysis patients need medication to prevent blood clots during treatment, and heparin is the most common choice. However, heparin can cause serious side effects including bone loss, allergic reactions, and a dangerous blood condition called heparin-induced thrombocytopenia. This trial is testing whether a simpler regional anticoagulation procedure (RAP)—which uses calcium re-injection instead of heparin—can work just as well while keeping patients safer.

Many dialysis patients receive large amounts of heparin every year, which increases their risk of bleeding and other complications. Researchers want to find out if this medication-free approach can prevent dangerous blood clots while reducing these risks.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been receiving hemodialysis for end-stage renal disease for at least 3 months, with sessions of at least 4 hours
your dialysis sessions have been working well without blood clots in the past 3 months
your calcium levels are normal based on your most recent blood test
you are affiliated with a social security or health insurance system

You likely don't qualify if…

you have a non-working or problematic vascular access (fistula or graft)
you are currently taking other blood-thinning medications
you have had recent bleeding, surgery, head trauma, or stroke within the last 7 days
you have a known allergy to heparin or a history of heparin-induced thrombocytopenia
you have liver disease or severe kidney disease complications like uremic pericarditis

What participation looks like

You would continue your regular dialysis sessions, but instead of receiving heparin injections, you would receive the new regional anticoagulation procedure, which involves calcium re-injection to prevent clotting. The study compares your results using both methods, so you would act as your own control. Researchers will monitor your blood work and dialysis session success to see how well this new approach works for you.

Testing a blood-clotting method without heparin for dialysis patients

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)